Javascript must be enabled to continue!
Intermittent Transdermal Nitroglycerin Therapy
View through CrossRef
Background
Intermittent transdermal nitroglycerin therapy is effective in the treatment of stable angina and prevents the development of tolerance. Previous investigations have suggested that removal of nitroglycerin patches may be associated with a decrease in anginal threshold. This study examines the effect of nitroglycerin patch removal on anginal threshold in a group of patients with stable angina.
Methods and Results
Twelve patients with stable angina were enrolled in a randomized, double-blind, placebo-controlled, crossover study. These patients had reproducible treadmill walking times and were taking no other long-acting antianginal medications or vasodilators. They received 0.8 mg/h transdermal nitroglycerin or wore a matching placebo patch for 5 to 7 days and then crossed over to the other treatment arm of the study. Transdermal nitroglycerin was applied at 8:00
pm
and removed at 8:00
am
each day. On the last day of each treatment period, patients underwent treadmill exercise testing at 8:00
am
(before patch removal) and at 2, 4, and 6 hours after patch removal. The primary end point was the treadmill walking time until moderate angina (P2). Other end points included the treadmill walking time until onset of angina (P1), the amount of ST segment depression at P1 and P2, and treadmill walking time until the development of 1 mm ST depression. Heart rate, systolic blood pressure, and the rate-pressure product were determined at rest before exercise and at P1 and P2. At 8:00
am
P1 and P2 were not significantly affected by active nitroglycerin compared with placebo, indicating the development of tolerance. Removal of the active transdermal nitroglycerin patch was associated with a significant decrease in the time to P1 at 2, 4, and 6 hours after patch removal compared with placebo. There was also a decrease in the time to P2 after active patch removal that was statistically significant compared with placebo at 2 and 4 hours and was of borderline significance at 6 hours. There were no differences in heart rate, blood pressure, or amount of ST segment depression at either P1 or P2 after active compared with placebo patch removal.
Conclusions
In patients with stable angina pectoris, intermittent transdermal nitroglycerin therapy is associated with a decrease in anginal threshold for 4 to 6 hours after patch removal. Although the cause of this phenomenon remains uncertain, it may be due to counterregulatory responses that develop during nitroglycerin patch application.
Ovid Technologies (Wolters Kluwer Health)
Title: Intermittent Transdermal Nitroglycerin Therapy
Description:
Background
Intermittent transdermal nitroglycerin therapy is effective in the treatment of stable angina and prevents the development of tolerance.
Previous investigations have suggested that removal of nitroglycerin patches may be associated with a decrease in anginal threshold.
This study examines the effect of nitroglycerin patch removal on anginal threshold in a group of patients with stable angina.
Methods and Results
Twelve patients with stable angina were enrolled in a randomized, double-blind, placebo-controlled, crossover study.
These patients had reproducible treadmill walking times and were taking no other long-acting antianginal medications or vasodilators.
They received 0.
8 mg/h transdermal nitroglycerin or wore a matching placebo patch for 5 to 7 days and then crossed over to the other treatment arm of the study.
Transdermal nitroglycerin was applied at 8:00
pm
and removed at 8:00
am
each day.
On the last day of each treatment period, patients underwent treadmill exercise testing at 8:00
am
(before patch removal) and at 2, 4, and 6 hours after patch removal.
The primary end point was the treadmill walking time until moderate angina (P2).
Other end points included the treadmill walking time until onset of angina (P1), the amount of ST segment depression at P1 and P2, and treadmill walking time until the development of 1 mm ST depression.
Heart rate, systolic blood pressure, and the rate-pressure product were determined at rest before exercise and at P1 and P2.
At 8:00
am
P1 and P2 were not significantly affected by active nitroglycerin compared with placebo, indicating the development of tolerance.
Removal of the active transdermal nitroglycerin patch was associated with a significant decrease in the time to P1 at 2, 4, and 6 hours after patch removal compared with placebo.
There was also a decrease in the time to P2 after active patch removal that was statistically significant compared with placebo at 2 and 4 hours and was of borderline significance at 6 hours.
There were no differences in heart rate, blood pressure, or amount of ST segment depression at either P1 or P2 after active compared with placebo patch removal.
Conclusions
In patients with stable angina pectoris, intermittent transdermal nitroglycerin therapy is associated with a decrease in anginal threshold for 4 to 6 hours after patch removal.
Although the cause of this phenomenon remains uncertain, it may be due to counterregulatory responses that develop during nitroglycerin patch application.
Related Results
Pharmacological Characterization of Orofacial Nociception in Female Rats Following Nitroglycerin Administration
Pharmacological Characterization of Orofacial Nociception in Female Rats Following Nitroglycerin Administration
Rodent models of human disease can be valuable for understanding the mechanisms of a disease and for identifying novel therapies. However, it is critical that these models be vette...
The effects of acute and preventive migraine therapies in a mouse model of chronic migraine
The effects of acute and preventive migraine therapies in a mouse model of chronic migraine
Background
The development of novel migraine therapies has been slow, in part because of the small number of clinically relevant animal models. We have recently...
KARAKTERISASI POLIMER L-3,4-dihydroxyphenylalanine (L-DOPA) PADA SISTEM PENGHANTARAN OBAT SEDIAAN PATCH TRANSDERMAL
KARAKTERISASI POLIMER L-3,4-dihydroxyphenylalanine (L-DOPA) PADA SISTEM PENGHANTARAN OBAT SEDIAAN PATCH TRANSDERMAL
Abstract. Vitamin B1 is one type of active substance needed by the body but has low Bioaccessibility when used orally. So, to prevent damage to the active vitamin B1 due to gastric...
Portal hemodynamics during nitroglycerin administration in cirrhotic patients
Portal hemodynamics during nitroglycerin administration in cirrhotic patients
Nitroglycerin is a potent venous dilator and a mild arterial vasodilator that has been shown to improve the hemodynamic response to vasopressin in portal hypertensive patients and ...
Pengaruh Puasa Intermiten Kering terhadap Kadar Kolesterol pada Mencit yang Diberi Pakan Tinggi Lemak
Pengaruh Puasa Intermiten Kering terhadap Kadar Kolesterol pada Mencit yang Diberi Pakan Tinggi Lemak
Abstract. Hypercholesterolemia is a condition when the total cholesterol level in the blood increases and the LDL cholesterol level in the blood exceeds the normal limit. High chol...
Artificially Constructing Microbial Consortia for Bioaugmentation of Nitroglycerin Degradation
Artificially Constructing Microbial Consortia for Bioaugmentation of Nitroglycerin Degradation
ABSTRACT
Nitroglycerin (NG), a recalcitrant and highly toxic nitroaromatic pollutant prevalent in wastewater from explosive manufacturing and pharmaceutical secto...
Effect of Topically Applied Milrinone or Nitroglycerin on Internal Mammary Artery Free Flow
Effect of Topically Applied Milrinone or Nitroglycerin on Internal Mammary Artery Free Flow
Background. Surgical mobilization of the internal mammary artery (IMA) can induce graft vasospasm, which is commonly managed by wrapping the IMA in a vasodilator‐soaked swab before...
Formulation, Development and Characterization of Transdermal Patches of Metformine Hydrochloride as Lοw Dοse Maintenance Therapy
Formulation, Development and Characterization of Transdermal Patches of Metformine Hydrochloride as Lοw Dοse Maintenance Therapy
The οbjective οf the prοpοsed study was tο develοp lοw dοse support treatment οf metformin hydrochloride in diabetic patients. The pοtassium brοmide pellet was mοunted in IR compar...

